drugset / Trial / NCT01573468
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.
Timeline
- Start
- 2012-04
- Primary completion
- 2014-07
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1750 mg/m2 | Oral |
| Subject | Tesetaxel | Small molecule | 27 mg/m2 | Oral |